Calpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type mice

Neurobiology of Aging

Volumn 33, Issue 6, 2012, Pages 1125.e9-1125.e18

  Morales Corraliza, Jose ^a,b   Berger, Jason D ^a   Mazzella, Matthew J ^a   Veeranna, ^a,b   Neubert, Thomas A ^b   Ghiso, Jorge ^b   Rao, Mala V ^a,b   Staufenbiel, Matthias ^c   Nixon, Ralph A ^a,b   Mathews, Paul M ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; APP; A ; Calpain; Calpastatin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CALPAIN; CALPASTATIN; MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SYNAPTIC TRANSMISSION; WILD TYPE;

EID: 84859502846     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.11.023     Document Type: Article

References (50)

1. Amadoro G., Ciotti M.T., Costanzi M., Cestari V., Calissano P., Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2892-2897.
2. Arthur J.S., Elce J.S., Hegadorn C., Williams K., Greer P.A. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol. Cell. Biol 2000, 20:4474-4481.
3. Azam M., Andrabi S.S., Sahr K.E., Kamath L., Kuliopulos A., Chishti A.H. Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Mol. Cell. Biol 2001, 21:2213-2220.
4. Bartus R.T., Elliott P.J., Hayward N.J., Dean R.L., Harbeson S., Straub J.A., Li Z., Powers J.C. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol. Res 1995, 17:249-258.
5. Carragher N.O. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr. Pharm. Des 2006, 12:615-638.
6. Chung S.H. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 2009, 42:467-474.
7. Croall D.E., DeMartino G.N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev 1991, 71:813-847.
8. Fifre A., Sponne I., Koziel V., Kriem B., Yen Potin F.T., Bihain B.E., Olivier J.L., Oster T., Pillot T. Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid β-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. J. Biol. Chem 2006, 281:229-240.
9. Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiol. Rev 2003, 83:731-801.
10. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science 2001, 293:1491-1495.
11. Grammer M., Kuchay S., Chishti A., Baudry M. Lack of phenotype for LTP and fear conditioning learning in calpain 1 knock-out mice. Neurobiol. Learn. Mem 2005, 84:222-227.
12. Grynspan F., Griffin W.R., Cataldo A., Katayama S., Nixon R.A. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 1997, 763:145-158.
13. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem 2005, 280:15229-15237.
14. Huang Y., Wang K.K. The calpain family and human disease. Trends Mol. Med 2001, 7:355-362.
15. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., Hamilton G., Powell J., Anderton B., Lovestone S. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett 2005, 373:1-4.
16. Klafki H., Abramowski D., Swoboda R., Paganetti P.A., Staufenbiel M. The carboxyl termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct γ-secretase activities. J. Biol. Chem 1996, 271:28655-28659.
17. Kuwako K., Nishimura I., Uetsuki T., Saido T.C., Yoshikawa K. Activation of calpain in cultured neurons overexpressing Alzheimer amyloid precursor protein. Brain Res. Mol. Brain Res 2002, 107:166-175.
18. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
19. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
20. Liang B., Duan B.Y., Zhou X.P., Gong J.X., Luo Z.G. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem 2010, 285:27737-27744.
21. Liu F., Grundke-Iqbal I., Iqbal K., Oda Y., Tomizawa K., Gong C.X. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J. Biol. Chem 2005, 280:37755-37762.
22. Maki M., Ma H., Takano E., Adachi Y., Lee W.J., Hatanaka M., Murachi T. Calpastatins: biochemical and molecular biological studies. Biomed. Biochim. Acta 1991, 50:509-516.
23. Mathews P.M., Guerra C.B., Jiang Y., Grbovic O.M., Kao B.H., Schmidt S.D., Dinakar R., Mercken M., Hille-Rehfeld A., Rohrer J., Mehta P., Cataldo A.M., Nixon R.A. Alzheimer's disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Aβ secretion: role for altered lysosomal hydrolase distribution in β-amyloidogenesis. J. Biol. Chem 2002, 277:5299-5307.
24. Mathews P.M., Jiang Y., Schmidt S.D., Grbovic O.M., Mercken M., Nixon R.A. Calpain activity regulates the cell surface distribution of amyloid precursor protein: inhibition of calpains enhances endosomal generation of β-cleaved C-terminal APP fragments. J. Biol. Chem 2002, 277:36415-36424.
25. Mi W., Pawlik M., Sastre M., Jung S.S., Radvinsky D.S., Klein A.M., Sommer J., Schmidt S.D., Nixon R.A., Mathews P.M., Levy E. Cystatin C inhibits β-amyloid deposition in Alzheimer's disease mouse models. Nat. Genet 2007, 39:1440-1442.
26. Morales-Corraliza J., Mazzella M.J., Berger J.D., Diaz N.S., Choi J.H., Levy E., Matsuoka Y., Planel E., Mathews P.M. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the β-amyloid depositing mice. PLoS One 2009, 4:e7134.
27. Nakajima R., Takao K., Huang S.M., Takano J., Iwata N., Miyakawa T., Saido T.C. Comprehensive behavioral phenotyping of calpastatin-knockout mice. Mol. Brain 2008, 1:7.
28. Nixon R.A. The calpains in aging and aging-related diseases. Ageing Res. Rev 2003, 2:407-418.
29. Nixon R.A., Cataldo A.M., Mathews P.M. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem. Res 2000, 25:1161-1172.
30. Pike B.R., Flint J., Dutta S., Johnson E., Wang K.K., Hayes R.L. Accumulation of non-erythroid αII-spectrin and calpain-cleaved αII-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J. Neurochem 2001, 78:1297-1306.
31. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of β-amyloid-protein by degradation. J. Biol. Chem 1998, 273:32730-32738.
32. Rao M.V., Mohan P.S., Peterhoff C.M., Yang D.S., Schmidt S.D., Stavrides P.H., Campbell J., Chen Y., Jiang Y., Paskevich P.A., Cataldo A.M., Haroutunian V., Nixon R.A. Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J. Neurosci 2008, 28:12241-12254.
33. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates β-amyloid-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
34. Saito K., Elce J.S., Hamos J.E., Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:2628-2632.
35. Schmidt S.D., Jiang Y., Nixon R.A., Mathews P.M. Tissue processing prior to protein analysis and β-amyloid quantitation. Methods Mol. Biol 2005, 299:267-278.
36. Schmidt S.D., Nixon R.A., Mathews P.M. ELISA method for measurement of β-amyloid levels. Methods Mol. Biol 2005, 299:279-297.
37. Siman R., Noszek J.C. Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron 1988, 1:279-287.
38. Sorimachi H., Ishiura S., Suzuki K. Structure and physiological function of calpains. Biochem. J 1997, 328:721-732.
39. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
40. Takano J., Tomioka M., Tsubuki S., Higuchi M., Iwata N., Itohara S., Maki M., Saido T.C. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J. Biol. Chem 2005, 280:16175-16184.
41. Tomidokoro Y., Rostagno A., Neubert T.A., Lu Y., Rebeck G.W., Frangione B., Greenberg S.M., Ghiso J. Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AβD23N in parenchymal and cerebrovascular amyloid deposits. Am. J. Pathol 2010, 176:1841-1854.
42. Trinchese F., Fa M., Liu S., Zhang H., Hidalgo A., Schmidt S.D., Yamaguchi H., Yoshii N., Mathews P.M., Nixon R.A., Arancio O. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest 2008, 118:2796-2807.
43. Vaisid T., Kosower N.S., Katzav A., Chapman J., Barnoy S. Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. Neurochem. Int 2007, 51:391-397.
44. Kaji T., Boland B., Odrljin T., Mohan P., Basavarajappa B.S., Peterhoff C., Cataldo A., Rudnicki A., Amin N., Li B.S., Pant H.C., Hungund B.L., Arancio O., Nixon R.A., Veeranna Calpain mediates calcium-induced activation of the ERK1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am. J. Pathol 2004, 165:795-805.
45. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci 2000, 23:20-26.
46. Wang K.K., Posmantur R., Nadimpalli R., Nath R., Mohan P., Nixon R.A., Talanian R.V., Keegan M., Herzog L., Allen H. Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch. Biochem. Biophys 1998, 356:187-196.
47. Warren M.W., Zheng W., Kobeissy F.H., Cheng Liu M., Hayes R.L., Gold M.S., Larner S.F., Wang K.K. Calpain- and caspase-mediated αII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int. J. Neuropsychopharmacol 2007, 10:479-489.
48. Yamazaki T., Haass C., Saido T.C., Omura S., Ihara Y. Specific increase in β-amyloid-protein 42 secretion ratio by calpain inhibition. Biochemistry 1997, 36:8377-8383.
49. Zatz M., Starling A. Calpains and disease. N Engl J. Med 2005, 352:2413-2423.
50. Zhang L., Song L., Parker E.M. Calpain inhibitor I increases β-amyloid peptide production by inhibiting the degradation of the substrate of γ-secretase. Evidence that substrate availability limits β-amyloid peptide production. J. Biol. Chem 1999, 274:8966-8972.